ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 777.8 USD | +1.45% |
|
-0.43% | +33.43% |
| 05-07 | Coca Cola's new bond prices tight, investors still hungry for new debt | RE |
| 05-07 | FDA Sets June 10 Advisory Panel Meeting on Eli Lilly Alzheimer's Drug | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
777.8
USD
Average target price
848.3
USD
Spread / Average Target
+9.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +33.43% | 690B | |
| +26.43% | 546B | |
| -5.12% | 358B | |
| +19.59% | 323B | |
| +4.89% | 287B | |
| +14.32% | 235B | |
| +5.79% | 199B | |
| -9.49% | 195B | |
| +4.26% | 161B | |
| -3.54% | 159B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- BMO Capital Starts Eli Lilly at Outperform With $311 Price Target